Reply to: “Incidence of grade 3–4 liver injury under immune checkpoints inhibitors: A retrospective study”
Author(s): ,
Didier Samuel
Affiliations:
AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France
Corresponding Author. Address: Centre Hépatobiliaire, Hôpital Paul Brousse, Groupe Hospitalier Paris Sud, DHU Hepatinov, RHU Ilite, 12 Avenue Paul Vaillan Couturier, 94800 Villejuif, France; Tel.: + 33 1 45 59 34 03; fax: + 33 1 45 59 38 57.
,
Catherine Guettier
Affiliations:
AP-HP Hôpital Bicêtre, Department of Pathology, Le Kremlin-Bicêtre, France
,
Aurelien Marabelle
Affiliations:
Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France
,
Caroline Robert
Affiliations:
Dermatology Unit, Department of Medical Oncology, Gustave Roussy, Paris Sud University, Villejuif, France
,
Olivier Lambotte
Affiliations:
APHP Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, Université Paris Sud, CEA, DSV/iMETI, Division of Immunovirology, IDMIT, INSERM, U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France
,
Stephane Champiat
Affiliations:
Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France
,
Barbara Papouin
Affiliations:
Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay, France
,
Jean-Marie Michot
Affiliations:
Département d'innovation thérapeutique et d'Essais Précoces (DITEP), Institut Gustave-Roussy, Université Paris Saclay, Villejuif, France
Eleonora De Martin
Affiliations:
AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, Univ Paris-Sud, UMR-S 1193, Université Paris-Saclay Villejuif, DHU Hepatinov, France
EASL LiverTree™. Samuel D. Dec 1, 2018; 256751
Prof. Didier Samuel
Prof. Didier Samuel
Contributions
Journal Abstract
References
This article does not have an abstract to display.
[1]. E. De Martin - Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
[2]. L. Vigano - Reversibility of chemotherapy-related liver injury
[3]. B. Sangro - A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
[4]. A.B. El-Khoueiry - Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
[5]. J. Larkin - Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
[6]. J.D. Wolchok - Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
[7]. M. Johncilla - Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies